ARKG tops GNOM in 2024, exposing genomics ETF structure gap
A 15-percentage-point return gap this year between the ARK Genomic Revolution ETF and the Global X Genomics & Biotechnology ETF highlights the stark trade-offs between active, concentrated biotech bets and passive, diversified strategies.
The ARK Genomic Revolution ETF (ARKG) has surged 32% year-to-date, outpacing the Global X Genomics & Biotechnology ETF (GNOM) at 17%. Both funds target gene editing, sequencing, and precision medicine, but their structural differences are driving a growing performance divergence.
ARKG operates as a concentrated, actively managed bet on pre-revenue and early-revenue platforms. Top holdings Twist Bioscience at 9.2%, Tempus AI at 7.6%, and Absci at 7.0% combine for 23.8% of the portfolio, with roughly 18% in gene-editing names and 16% in AI-driven drug discovery. This high-conviction approach relies heavily on cheap capital, risk appetite, and clinical catalysts—macro conditions currently supported by falling interest rates and a reviving biotech M&A market.
Conversely, GNOM tracks the Solactive Genomics Index with a broader portfolio of 51 positions. It anchors its exposure in established, cash-flowing giants like Illumina at 4.6%, Moderna at 4.3%, and Vertex Pharmaceuticals at 3.8%, alongside large-cap pharma names such as Bristol-Myers Squibb, Gilead, and AstraZeneca. This passive construction and regular index reconstitution limit the impact of single-name failures, offering category-level compounding with significantly lower volatility.
For institutional and large retail investors, liquidity separates the two vehicles. ARKG holds $1.4 billion in assets compared to GNOM's $75 million. That vast size disparity gives the larger fund meaningfully tighter bid-ask spreads and superior execution for block trades, making it the more practical choice for traders needing to move in and out of positions efficiently.
Despite ARKG's recent dominance, its long-term record introduces a different risk calculus, having lost 13 more percentage points than its passive peer over the past five years. Market professionals view GNOM as a suitable core holding for long-term portfolios due to its lower drawdown risk, while ARKG functions best as a high-risk satellite position. Investors allocating to ARKG must size the position carefully to survive another potential 50% drawdown.
